Unlisted Woodford darling receives £50m injection
California pharma giant invests in Oxford Nanopore
California pharma giant invests in Oxford Nanopore
Assets under management grow 18.5% due to the deal
Wealth manager saw previous CEO and another senior executive depart within a week of each other
Assets grew 8% year-on-year ahead of landing £30bn Lloyds mandate
Buyer will not take on potential liabilities linked to mass mis-selling claims
Slice of the £109bn mandate would boost sluggish AUM growth
But industry commentators argue it will be ‘a low margin business’
Emerging market debt leads inflows at the specialist fund house
CEO blames weak investor sentiment for industry-wide slowdown in retail flows
Fixed income remains fund house’s Achilles’ heel as smaller rivals enjoy asset growth
Compliance issues that resulted in Tim Haywood’s exit hit reputation and flows
Total net inflows see a near threefold increase year-on-year